Top

Published in:

01-05-2016 | Capsule Commentary

Capsule Commentary on Castro et al., Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients

Author: Alice Ching, MD

Published in: Journal of General Internal Medicine | Issue 5/2016

Excerpt

Every medical decision is a balance between potential benefit and potential risk. Statins have recently been associated with an increased risk of developing diabetes, which has raised concerns given their widespread use.1 Castro et al.2 investigated the association between statin use and the risk of diabetes and overall mortality in an observational cohort study of over 18,000 non-diabetic patients over a 6-year period. The authors found that statins were associated with an increased risk of developing diabetes and a similar reduction in mortality, and conclude that the overall benefit of statins outweigh the incident diabetes risk. …

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.CrossRefPubMed

Castro MR, Simon G, Cha SS, et al. Statin use, diabetes incidence and overall mortality in normoglycemic and impaired fasting glucose patients. J Gen Intern Med. doi: 10.1007/s11606-015-3583-0

Macedo AF, Douglas I, Smeeth L, et al. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice research datalink. BMC Cardiovasc Disord. 2014;14:85.CrossRefPubMedPubMedCentral

Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841.CrossRefPubMed

Title: Capsule Commentary on Castro et al., Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients
Author: Alice Ching, MD
Publication date: 01-05-2016
Publisher: Springer US
Published in: Journal of General Internal Medicine / Issue 5/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-016-3638-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2016

VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class Analysis

Capsule Commentary on Alkureishi et al., Impact of Electronic Medical Record Use on the Patient–Doctor Relationship and Communication: A Systematic Review

Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial

Capsule Commentary on Calcaterra et al., Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use

Muscle Hypertrophy in a Patient with Immunoglobulin D Multiple Myeloma

Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials